Hypercholesterolemia in Acute Coronary Syndrome Patients in India - A Retrospective Real- World Evidence Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 558
- 试验地点
- 11
- 主要终点
- To assess LDL-C control (less Than 55 mg/dL) in patients with ACS with current available treatments
研究概览
简要总结
-
Cardiovascular disease (CVD) is leading cause of death worldwide, accounting for about 31% of global death (WHO, 2018)
-
In India, CVD is responsible for about 27% of all deaths (WHO, 2018)
-
Atherosclerosis cardiovascular disease (ASCVDs) are associated with a substantial mortality, physical morbidity, and mrtal disability. India has been experiencing an epidemic of ASCVD, which has suppressed infectious diseases as the leading cause of death among Indians.
Elevated plasma low-density lipoprotein cholesterol (LDL-C) level play a major role in the pathophysiology of ASCVDs ( Auer and Berent,2018)
-
No major study exists currently that could hlep identify the level of LDL-C control amongst Indian acute Coronary syndrome (ACS) patients, especially as per the revised LAI consensus and other global guidelines.
-
The present study is therefore being conducted to evaluate the real world experience related to the treatment patterns and LDL-C control in ACS patients.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients aged >18 years.
- •Patients with ACS event [One or more of the following: ST-segment-elevation myocardial infarction or left bundle branch block myocardial infarction (STEMI/LBBB MI), a non-ST-segment-elevation myocardial infarction (NSTEMI), or UA with or without PCI/ CABG.
- •Lipid profile data available at index date/15 days of index date and at least once at 3, 6, 9, 12 months post-index date ACS event.
排除标准
- •Patients meeting any of the following criteria will not be included in the study:
- •Incomplete paper-based records/EMRs data.
- •Non-availability of paper-based records/EMRs for 12 months’ time point post index date ACS event.
结局指标
主要结局
To assess LDL-C control (less Than 55 mg/dL) in patients with ACS with current available treatments
时间窗: Time Frame: Baseline, Months 3, 6, 9, and 12
次要结局
- In patients with ACS with current available treatments(A. To Assess LDL-C control (Less Than 30, Less Than 50, Less than 70, Less Than 100 mg/dL) B. To assess Lp(a) testing and control C. To study the change in lipid profile parameters D. To assess treatment pattern of statin positive or negative, other lipid lowering drugs, statin intolerance E. To assess tolerability-of LLTs F. To assess demographic profile, clinical characteristics, and concomitant medications)